Status:
COMPLETED
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Osteogenesis Imperfecta
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Osteogenesis Imperfecta (OI) is a heterogeneous group of rare connective tissue hereditary diseases responsible for fragility and bone deformity. OI is caused by an autosomal dominant mutation of COL1...
Eligibility Criteria
Inclusion
- Control population:
- Male or female
- 18 years old and over
- Be part of cohorts STRAMBO, OFELY or MODAM
- Patients with OI:
- Male or female ≥18 years old
- Have COL1A1 or COL1A2 mutation
- Have a diagnosis of type 1 or 3 from Silence classification made by a rheumatologist expert in bone pathologies
Exclusion
- Refusal to participate in the study
- Have received glucocorticoid treatment for more than 3 months
- Have received anti-osteoporotic treatment for less than 1 year ago
- Have Chronic inflammatory rheumatism
- Have an uncontrolled hypo/hyper thyroidism ou hypo/hyper parathyroidism
- Have cancer or bone metastases (current or in the past two years)
- Have benign bone tumors or Paget's disease
- Have malabsorptive disease (Celiac disease, Whipple's disease, intestinal bypass, short bowel syndrome) and inflammatory bowel disease
- Pregnant or lactating women
- Have psychiatric disorders seriously hindering understanding
- Have difficulties in oral understanding of French language
- Not a beneficiary of french social security
- Patients protected by law
Key Trial Info
Start Date :
October 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 24 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04009733
Start Date
October 3 2019
End Date
April 24 2022
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, France, 69003